JP2004143154A5 - - Google Patents

Download PDF

Info

Publication number
JP2004143154A5
JP2004143154A5 JP2003336240A JP2003336240A JP2004143154A5 JP 2004143154 A5 JP2004143154 A5 JP 2004143154A5 JP 2003336240 A JP2003336240 A JP 2003336240A JP 2003336240 A JP2003336240 A JP 2003336240A JP 2004143154 A5 JP2004143154 A5 JP 2004143154A5
Authority
JP
Japan
Prior art keywords
observed
edema
cedar pollen
instilled
scored
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003336240A
Other languages
Japanese (ja)
Other versions
JP2004143154A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2003336240A priority Critical patent/JP2004143154A/en
Priority claimed from JP2003336240A external-priority patent/JP2004143154A/en
Publication of JP2004143154A publication Critical patent/JP2004143154A/en
Publication of JP2004143154A5 publication Critical patent/JP2004143154A5/ja
Pending legal-status Critical Current

Links

Description

試験例
試験方法:実施例1、2、3、4、7、8及び9の点眼剤と表2に示した比較例1〜4の点眼剤を検体として用いた。スギ花粉を用いて感作したモルモット30匹を、スギ花粉惹起30分後の目のアレルギー症状が均等になるように1群8〜13匹に群分けした。各検体をモルモットの両眼に10μL点眼し、5分後にスギ花粉0.5mg(生食懸濁液10μL)を両目に点眼した。非点眼群は、スギ花粉のみ点眼した。スギ花粉投与後30分後の角結膜の状態を肉眼的に観察した。なお、角結膜の状態の評価はDraize法に準じて、発赤を0〜2の3段階、浮腫を0〜4の5段階、分泌物を0〜3の4段階(トータルスコアー9)でスコアー化した。各状態の評価を下記に示す。このスコアーよりアレルギー症状の改善率(%)を下記式にて算出し、表3に示した。
改善率(%)=100−[(点眼群のトータルスコアーの平均値)/(非点眼群のトータルスコアーの平均値)×100]
発赤
0:充血が全く認められない
1:結膜の一部に充血が認められる
2:結膜全体に充血が認められる
浮腫
0:浮腫が全く認められない
1:結膜の一部に軽い浮腫を認める
2:結膜全体に浮腫が認められる
3:浮腫が角膜の一部を覆っている
4:浮腫が角膜の半分以上を覆っている
分泌物
0:分泌物を認めない
1:明らかな涙液様の分泌物が認められる
2:粘性のある分泌物が認められる
3:分泌物が膜状になり眼瞼を覆っている
Test Example Test method: The eye drops of Examples 1, 2, 3, 4 , 7 , 8, and 9 and the eye drops of Comparative Examples 1 to 4 shown in Table 2 were used as samples. Thirty guinea pigs sensitized with cedar pollen were divided into groups of 8 to 13 animals so that allergic symptoms of the eyes 30 minutes after the cedar pollen induction were uniform. 10 μL of each sample was instilled into both eyes of a guinea pig, and 5 minutes later, 0.5 mg of cedar pollen (10 μL of a saline solution) was instilled into both eyes. In the non-instilled group, only cedar pollen was instilled. The state of the keratoconjunctiva 30 minutes after administration of the cedar pollen was visually observed. The evaluation of the keratoconjunctival condition was scored according to the Draize method according to the Draize method, with redness scored in three stages of 0-2, edema scored in five stages of 0-4, and secretions scored in four stages of 0-3 (total score of 9). did. The evaluation of each state is shown below. From this score, the improvement rate (%) of allergic symptoms was calculated by the following formula, and shown in Table 3.
Improvement rate (%) = 100 − [(average value of total score of eye drop group) / (average value of total score of non-drop group) × 100]
Redness 0: No congestion is observed at all. 1: Hyperemia is observed at a part of conjunctiva. 2: Edema is observed at entire conjunctiva. 0: No edema is observed. 1: Light edema is observed at a part of conjunctiva. : Edema covers the entire conjunctiva 3: Edema covers part of the cornea 4: Secretion in which edema covers more than half of the cornea 0: No secretion is observed 1: Clear tear-like secretion Objects are observed 2: Viscous secretions are observed 3: Secretions are film-like and cover eyelids

Figure 2004143154
Figure 2004143154

JP2003336240A 2002-10-01 2003-09-26 Ophthalmic solution Pending JP2004143154A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003336240A JP2004143154A (en) 2002-10-01 2003-09-26 Ophthalmic solution

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002288407 2002-10-01
JP2003336240A JP2004143154A (en) 2002-10-01 2003-09-26 Ophthalmic solution

Publications (2)

Publication Number Publication Date
JP2004143154A JP2004143154A (en) 2004-05-20
JP2004143154A5 true JP2004143154A5 (en) 2006-07-06

Family

ID=32473330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003336240A Pending JP2004143154A (en) 2002-10-01 2003-09-26 Ophthalmic solution

Country Status (1)

Country Link
JP (1) JP2004143154A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012144570A (en) * 2005-04-19 2012-08-02 Daiichi Sankyo Healthcare Co Ltd Medicinal preparation to be applied to local mucous membrane containing ketotifen fumarate
JP5080745B2 (en) * 2005-04-19 2012-11-21 第一三共ヘルスケア株式会社 Pharmaceutical composition for topical mucosa containing ketotifen fumarate
CN101528211B (en) * 2006-08-28 2012-10-10 千寿制药株式会社 Ophthalmic percutaneous absorption type preparation

Similar Documents

Publication Publication Date Title
CN103269686B (en) Contact lens ophthalmic composition
Ren et al. Evaluation of three different methods to establish animal models of Acanthamoeba keratitis
CY1110758T1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF A RING OF A EYE
AU2019212565B2 (en) Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
CN105792848A (en) Aqueous composition for ophthalmological use or otolaryngological use
Fogagnolo et al. Tear film osmolarity, ocular surface disease and glaucoma: a review
CN1604784A (en) Heparin-containing ophthalmic agent
JP2004143154A5 (en)
JP5132015B2 (en) Eye drop composition
JP2002020279A (en) Eye lotion
CN1241912C (en) Disulfide derivatives useful for treating allergic diseases
JP6449774B2 (en) Ophthalmic composition for zwitterionic soft contact lenses
JP2017036255A (en) Ophthalmic composition
JP2005247821A (en) Ophthalmic composition for suppressing production of inflammatory cytokine
CN101347619A (en) Medicament composition and use thereof in preparing medicament for treating inflammation of eye section
WO2006118170A1 (en) Therapeutic agent for corneal disease
DE60124732T2 (en) GATIFLOXACIN AS INHIBITOR OF CYTOKIN PRODUCTION
JP2019038783A (en) Dry eye therapeutic agent
RU2003111602A (en) METHOD FOR DIAGNOSTIC OF DEGREE OF EXPRESSION OF DISORDERS OF HIGHER BRAIN FUNCTIONS
WO2023280319A1 (en) Application of loxoprofen sodium in preparation of drug for treating dry eye disease
Singh Assessment of the cause of Conjunctivitis in Adolescent Population
JP6401699B2 (en) Ophthalmic composition for zwitterionic soft contact lenses
JPWO2007023877A1 (en) Treatment for corneal diseases
Maślińska et al. The Risk of Infection in Dry Eye Syndrome Accompanying Primary Sjögren’s Syndrome
JP2004143154A (en) Ophthalmic solution